AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02938312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Plus
Description: Participants attend in-person meetings as described above. This condition also includes community-wide strategies to increase access to healthy affordable food and safe opportunities for physical activity.
Study NCT02398396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4CMenB (Bexsero®) - Novartis Vaccines and Diagnostics
Description: 4CMenB vaccine (Bexsero - Novartis Vaccines and Diagnostics) 0.5ml intra-muscularly; two doses, administered 2 months apart. Each dose of vaccine contains recombinant Neisseria meningitidis group B NHBA fusion protein (50 micrograms); recombinant Neisseria meningitidis group B NadA protein (50 micrograms); recombinant Neisseria meningitidis group B FHbp fusion protein (50 micrograms) and Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 (25 micrograms measured as amount of total protein containing the PorA P1.4)
Study NCT04286399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Renin-angiotensin-aldosterone system inhibitors
Description: Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
Study NCT04286399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Beta blocker
Description: Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
Study NCT04286399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product
Description: Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
Study NCT01146834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib (Velcade)
Description: 1.3 mg/m2 IVP on days 1, 4, 8 and 11
Study NCT01146834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)
Study NCT01146834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C and start on Day 1 for Arm D)
Study NCT02276157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct peroral cholangioscopy
Description: The multibending (MB) or conventional ultra-slim endoscope was inserted through the mouth. After facing the papillary orifice, the endoscope was inserted directly, without any accessories, into the distal bile duct. The second bending of the MB ultra-slim endoscope was kept in an upward angled position to achieve a more acute angle of the endoscope tip for entering the distal CBD. Then, the endoscope was pushed by steering the first bend into an upward angle (α shape) or the endoscope was pulled by steering the first bend into an upward angle and torqueing it counter-clockwise (u shape) for insertion into the distal CBD. If the distal bile duct was visualized on an endoscopic view, carbon dioxide insufflation was stopped. The endoscope was advanced into the hilum or the obstructed segment of the extrahepatic bile duct under fluoroscopic and endoscopic control. Then, the diagnostic and therapeutic interventions were performed during direct POC as necessary.
Study NCT02276157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct peroral cholangioscopy
Description: The multibending (MB) or conventional ultra-slim endoscope was inserted through the mouth. After facing the papillary orifice, the endoscope was inserted directly, without any accessories, into the distal bile duct. The second bending of the MB ultra-slim endoscope was kept in an upward angled position to achieve a more acute angle of the endoscope tip for entering the distal CBD. Then, the endoscope was pushed by steering the first bend into an upward angle (α shape) or the endoscope was pulled by steering the first bend into an upward angle and torqueing it counter-clockwise (u shape) for insertion into the distal CBD. If the distal bile duct was visualized on an endoscopic view, carbon dioxide insufflation was stopped. The endoscope was advanced into the hilum or the obstructed segment of the extrahepatic bile duct under fluoroscopic and endoscopic control. Then, the diagnostic and therapeutic interventions were performed during direct POC as necessary.
Study NCT01883323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: i.v., 60mg/kg per day for 2 days
Study NCT04322357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: A 12-month treatment period with twice weekly, low-dose prednisone (dose of 0.75 mg/kg per day).
Study NCT01146834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5, plerixafor daily until stem cell collection is complete (Arm D), start on Day 12, approximately 11 hours prior to stem cell collection attempt and plerixafor daily until collection if complete (Arm E)
Study NCT03353246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InfraScanner 2000™
Description: The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
Study NCT04322357 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-home Exercise Training
Description: For boys on current standard of care (daily glucocorticoid use), 6-months in-home, remotely supervised exercise training program involving a combination of aerobic and isometric leg strength exercises.
Study NCT04322357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone plus exercise
Description: Twice weekly prednisone for 6 months followed by twice weekly prednisone plus exercise for 6 months.
Study NCT04188028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 5 MG
Description: dextromethorphan 5 mg po
Study NCT04188028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine 10Mg Tablet
Description: Paroxetine 10 mg po
Study NCT04188028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine 20Mg Tablet
Description: Paroxetine 20 mg po
Study NCT06263686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasteurised yoghurt
Description: Pasteurised (heat treated) natural yoghurt containing \<15 CFU/g of Lactobacillus delbrueckii bulgacirus and \<15 CFU/g of Streptococcus thermophilus.
Study NCT06263686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh yoghurt
Description: containing ≥ 108 CFU/g of Lactobacillus delbrueckii bulgacirus and ≥ 108 CFU/g of Streptococcus thermophilus
Study NCT06263686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterilised yoghurt
Description: Not containing viable bacteria
Study NCT04225871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zilucoplan (RA101495)
Description: Daily subcutaneous (SC) injection
Study NCT03523091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100Unit Injection
Description: Initial treatment with the option of repeat injections every 3 months
Study NCT02490982 — intervention group
Intervention type: DRUG
Intervention: Teriflunomide
Description: The prescription of Teriflunomide administered orally as a 14mg daily compound to RRMS patients.
Study NCT01105572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intel Health Guide
Description: An Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback, and also transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager.
Study NCT01105572 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Case Management
Description: Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes. Specially trained Medicare Case Managers collaborate with the member, family, caregiver, member authorized representative, treating practitioner, health care provider, community services and other Aetna programs to coordinate care, with a focus on member education and maximizing quality outcomes.
Study NCT04472806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab, humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.~Toripalimab treatment after chemotherapy in combination with Endostar, 240 mg, Q3W, up to 2 years.
Study NCT04472806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy in combination with Endostar
Description: chemotherapy+ Endostar
Study NCT05255718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aronia juice
Description: Once daily dose of 100 mL of aronia juice
Study NCT05255718 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily dose of 100 mL of placebo juice containing no polyphenols and matched to experimental Aronia juice in color, taste, and macronutrient content
Study NCT04658615 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-surgical periodontal therapy
Description: A single 1-hour session of full-mouth debridement with an ultrasonic device under local anesthesia
Study NCT02989662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Description: Participants receive 6 doses.
Study NCT02989662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: Participants receive 6 doses
Study NCT02233868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: connectivity
Description: Magnetic resonance imaging (MRI) scans will be done to assess brain structure, functional reactivity and functional connectivity.
Study NCT02233868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neuroinflammation
Description: The use of \[11C\]PBR28 will allow us to assess for the first time in vivo if there is neuroinflammation in the brain of alcoholics. It will also allow us to assess if it recovers with alcohol detoxification.
Study NCT02233868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neurofunction
Description: To assess regional brain glucose metabolism.
Study NCT01875601 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-15 (rhIL-15)
Description: Continuous infusion rhIL15 IV
Study NCT01875601 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cell Infusion
Description: Infuse expanded NK cells at Day 0 after 2 days of Cyclophosphamide lymphodepletion
Study NCT02699307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: OT led counseling
Study NCT03477812 — intervention group
Intervention type: DEVICE
Intervention: Polysomnography (Full sleep registration)
Description: For the healthy children two nights of polysomnography. For the children with nocturnal enuresis one night of polysomnography.
Study NCT03104543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: 30 minute education session; 15 minute booster session at 4 months
Study NCT03104543 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Test results only
Description: The control group will receive a copy of test results upfront but not experimental educational materials; those will be available at 1 year
Study NCT01836354 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DESERVE education
Description: Those patients assigned to education will receive stroke comprehensive intervention which focuses on three main areas, Risk perception, Medication Adherence, and Patient-Physician Communication. We will test whether phone calls and visits with a health worker after discharge, videos and a workbook are linked to better control of blood pressure and other risk factors
Study NCT02740556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HepCure ToolKit
Description: HepCure is a web-based tool kit in the form of a dashboard for providers and an application (or app) for patients. The app allows patients to become active participants in their treatment by enabling them to enter prescribed treatment, add medications to Pill Box, log doses, visualize adherence, and includes several additional resources.
Study NCT02740556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AdhereTech Active Features
Description: AdhereTech, a wireless pill monitoring device that measures the dosage and time a medication was taken. It is a HIPAA-compliant, FDA-registered Class I medical device. Using cellular technology, AdhereTech can be used passively to collect data on when a medication is taken, when a refill is needed, and how often the bottle is opened. AdhereTech also can be used actively to monitor adherence and provide feedback to subjects using the device. When actively monitoring, AdhereTech can be set up to provide live feedback to a subject by lighting up, sounding chimes, and sending phone/text/email alerts to remind patients to take their medication.
Study NCT02740556 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AdhereTech Passive Monitoring
Description: AdhereTech passively monitors adherence (no chimes or reminders)
Study NCT02740556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AdhereTech Passive Monitoring
Description: AdhereTech passively monitors adherence (no chimes or reminders)
Study NCT03894800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methoxyflurane (M)
Description: The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention inhalation of metoxyflurane 3 ml and NaCl i.v. will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
Study NCT03894800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl (F1)
Description: The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.025 mg i.v. and NaCl for inhalation will be administered(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
Study NCT03894800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl (F2)
Description: The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.05 mg i.v. and NaCl for inhalation will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
Study NCT03894800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl (C)
Description: The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention NaCl i.v. and NaCl inhal will be used - placebo(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
Study NCT04573985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious game Eurekoi intervention
Description: 1 session in group using the serious game eurekoi
Study NCT03894800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl (C)
Description: The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention NaCl i.v. and NaCl inhal will be used - placebo(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
Study NCT03396159 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mini fluid challenge
Description: mini fluid challenge will be given to diagnose if patient is need fluid resuscitation or not
Study NCT04743648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Innovative Thinking Development Program (ITDP)
Description: With the implementation of the program, nursing students are expected to develop innovative thinking skills.
Study NCT00659425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
Study NCT00659425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
Study NCT00659425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
Study NCT00659425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
Study NCT00659425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
Study NCT00659425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
Study NCT00659425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
Study NCT00659425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 (Moxetumomab Pasudotox)
Description: Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
Study NCT03059758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: All participants are scanned while evaluating deductive reasoning problems. Their math skill is also assessed.
Study NCT02056977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titration
Description: Individualized PEEP according to PEEP titration monitored by EIT
Study NCT02056977 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: PEEP selected according to a PaO2/FIO2 table as in the routines of the institution
Study NCT00846235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aqualan L, Aqualan Plus, Aqualan L + glycerol ad 20%
Description: moisturising cream twice daily three weeks